Skip to Main Content

An experimental drug from Cytokinetics (CYTK) failed to improve the lung function of patients with ALS compared to a placebo. The company presented the negative outcome from a mid-stage clinical trial at a neurology conference on Sunday.

This is the second setback for Cytokinetics and its efforts to develop an effective treatment for ALS, a degenerative nerve disorder that is almost always fatal, typically from respiratory failure.


In late 2017, the South San Francisco-based biotech discontinued the development of a predecessor ALS drug due to poor results from a Phase 3 clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!